Showing 141 - 160 results of 74,815 for search '(( a non decrease ) OR ( 5 ((((ng decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 0.82s Refine Results
  1. 141

    Table_2_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.docx by Casey E. Vantucci (10528263)

    Published 2022
    “…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …”
  2. 142

    Image_1_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.jpeg by Casey E. Vantucci (10528263)

    Published 2022
    “…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …”
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149

    Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression. by Megan Stevens (3964886)

    Published 2019
    “…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
  10. 150
  11. 151
  12. 152
  13. 153
  14. 154

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  15. 155
  16. 156
  17. 157
  18. 158

    Data_Sheet_1_Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity.d... by Chantal C. Clark (10684632)

    Published 2021
    “…</p><p>Conclusion: We observed an association between the use of preexisting thromboprophylaxis and a decreased risk of TE during COVID-19. This suggests that these therapies are beneficial for coping with COVID-19 associated hypercoagulability. …”
  19. 159

    Decrease in accelerometer assessed physical activity during the first-year post-myocardial infarction: a prospective cohort study by Amanda Lönn (11583010)

    Published 2024
    “…Patients included during covid-19 restrictions and younger patients had a higher level of moderate-intensity physical activity compared to patients included during non-pandemic restrictions and older patients. …”
  20. 160